Ventricular Septal Defect (VSD) Repair in India and UAE | Complete Patient Guide

• Eligibility — Surgical Repair (Open):

• Perimembranous or outlet VSDs of any size associated with hemodynamic compromise (Qp:Qs ≥ 2:1)

• Any VSD with associated aortic valve prolapse or regurgitation, regardless of shunt size

• VSDs causing symptomatic congestive heart failure (CHF), failure to thrive, or recurrent pulmonary infections refractory to medical management

• Infants with large unrestrictive VSDs and weight ≥ 3.5 kg (lower weight may require initial pulmonary artery banding as a bridge)

• Adults with previously unrepaired VSDs with preserved pulmonary vascular reactivity (PVR < 8 Wood Units or reversible on vasodilator testing)

• Eligibility — Transcatheter Device Closure:

• Muscular VSDs with favorable rim anatomy (≥ 4 mm from aortic and tricuspid valves, ≥ 4 mm rims)

• Perimembranous VSDs in select anatomical configurations (assessed by 3D transesophageal echocardiography)

• Residual or recurrent VSDs post-surgical repair

• Weight typically ≥ 5 kg for catheter-based access (though smaller patients may qualify at expert centers)

• Required Diagnostic Workup:

• Transthoracic Echocardiography (TTE) — first-line imaging; Doppler assessment of shunt direction, velocity, estimated right ventricular systolic pressure (RVSP), and defect morphology

• Transesophageal Echocardiography (TEE) or 3D TEE — precise anatomical delineation for surgical/device planning and intraoperative guidance

• Cardiac MRI (CMR) — quantification of Qp:Qs, ventricular volumes, and myocardial function, particularly in complex anatomy

• Cardiac Catheterization with hemodynamic study — mandatory when PAH is suspected; includes PVR calculation and nitric oxide vasoreactivity testing

• Chest X-ray — cardiomegaly, pulmonary plethora assessment

• 12-lead ECG — right ventricular hypertrophy patterns, conduction abnormalities

• Full Blood Count, Coagulation Profile, Renal and Hepatic Function Tests, Blood Group & Crossmatch

• Genetic and chromosomal testing (e.g., array-CGH, FISH for 22q11.2 deletion) when syndromic associations (Down syndrome, DiGeorge syndrome) are suspected

• Absolute Contraindications:

• Established Eisenmenger syndrome (irreversible PAH with PVR > 8 Wood Units, non-reactive to vasodilators, resting oxygen saturation < 90% on room air with right-to-left shunting)

• Active systemic infection or sepsis (procedure must be deferred until resolution)

• Severe uncorrected coagulopathy unresponsive to medical management

• Unfavorable VSD anatomy for device closure (inadequate rims, proximity to conduction system) — routes patient toward surgical repair rather than absolute contraindication to any intervention

1. OPEN SURGICAL REPAIR (Gold Standard)

Performed under general anesthesia via median sternotomy, with the patient placed on cardiopulmonary bypass (CPB) using a membrane oxygenator. Myocardial protection is achieved through antegrade cold blood cardioplegia (del Nido cardioplegia is widely favored in pediatric centers for its single-dose, prolonged arrest duration). The defect is approached through a right atriotomy (transatrial approach — the preferred technique, preserving right ventricular function), or occasionally through the right ventricle (transventricular) or pulmonary artery (transpulmonary) for outlet VSDs. Closure is accomplished with a patch — autologous glutaraldehyde-fixed pericardium or knitted Dacron — secured with interrupted or continuous pledgeted polypropylene sutures, with meticulous care to avoid the atrioventricular node (Koch's triangle), the bundle of His, and its left and right bundle branches, which course along the inferior margin of perimembranous defects. Intraoperative TEE confirms complete closure and excludes residual shunts or valve compromise before CPB weaning. Total CPB time averages 60–90 minutes; aortic cross-clamp time 30–60 minutes.

2. MINIMALLY INVASIVE SURGICAL REPAIR

Right lateral mini-thoracotomy (3–5 cm incision) with peripheral CPB cannulation (femoral or axillary vessels in adults; internal jugular + femoral in pediatric patients) provides excellent cosmetic outcomes and reduced sternal morbidity. Robotic-assisted VSD repair using the da Vinci Surgical System is offered at select high-volume centers in India (e.g., Sri Sathya Sai Institute, Apollo Hospitals Hyderabad) for anatomically suitable adult or adolescent patients, enabling 3D magnified visualization and precise suture placement through sub-centimeter ports. Port-access endoscopic repair is an intermediate option between sternotomy and full robotics.

3. TRANSCATHETER DEVICE CLOSURE

Performed under general anesthesia or deep sedation with continuous TEE and fluoroscopic guidance in a hybrid catheterization laboratory. Femoral venous access is obtained; a long sheath is advanced across the defect via a transseptal or direct trans-VSD approach. Device selection is anatomy-dependent:

• Amplatzer Muscular VSD Occluder (Abbott): self-centering nitinol mesh with polyester fabric; first-line for muscular VSDs

• Amplatzer Membranous VSD Occluder / Piccolo device: for perimembranous VSDs with eccentric disc design to avoid AV nodal injury

• Lifetech CeraFlex / CeraTM Occlutech devices: ceramic-surface nitinol devices with reduced nickel ion leakage and lower thrombogenicity

Post-deployment, device position is confirmed with both fluoroscopy and TEE before release. The procedure eliminates CPB, sternal incision, and associated morbidity, with discharge typically within 48–72 hours.

4. HYBRID (PERVENTRICULAR) APPROACH

Employed for complex muscular VSDs, multiple 'Swiss-cheese' defects, or in critically ill infants where CPB poses prohibitive risk. The cardiac surgeon exposes the right ventricle through a limited sternotomy; a needle is introduced directly through the right ventricular free wall under TEE guidance, and a muscular VSD occluder is deployed without CPB. This approach is also used in neonates with very low birth weight as a bridge or definitive therapy.

5. PULMONARY ARTERY BANDING (PAB) — Palliative Interim Measure

In premature neonates (< 2 kg) or infants with multiple comorbidities making primary repair high-risk, surgical banding of the main pulmonary artery reduces excessive pulmonary blood flow and prevents progressive PAH, deferring definitive repair until the patient is an optimal candidate. PAB is not curative and requires a second-stage surgical takedown with VSD closure.

6. MEDICAL MANAGEMENT (Adjunct — Not Definitive)

Anti-congestive therapy with loop diuretics (furosemide), aldosterone antagonists (spironolactone), and ACE inhibitors (captopril/enalapril) is used to optimize the patient's condition pre-operatively and in small restrictive VSDs anticipated to close spontaneously. Up to 50–75% of small muscular VSDs and 30% of small perimembranous VSDs close spontaneously by age 2–4 years; these patients are monitored with serial echocardiography.

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 Weeks Before Travel)

• Patient/family submits medical records (echocardiogram reports, cardiac catheterization data, prior surgical notes, growth charts) to GAF Healthcare's medical team

• Remote multidisciplinary review by a pediatric cardiac surgeon, pediatric cardiologist, and cardiac anesthesiologist at the chosen center

• Provisional surgical or interventional plan communicated in writing, including procedure type, estimated cost, and risk stratification

• Medical visa application initiated for India (e-Medical Visa + attendant e-Medical Visa); UAE entry formalities confirmed

• Pre-travel checklist provided: current medications, weight/height (critical for pediatric dosing and device sizing), recent blood work

PHASE 2 — ARRIVAL & IN-HOSPITAL PRE-OPERATIVE ASSESSMENT (Days 1–3)

• Airport pickup arranged by GAF Healthcare; transfer to hospital or affiliated accommodation

• Comprehensive inpatient workup: TTE, TEE (if not recently performed), cardiac MRI or catheterization as indicated, complete blood panel, coagulation screen, cross-match, anesthesia assessment, pediatric cardiology ward rounds

• Nutritional optimization: if the patient is a malnourished infant, enteral feeding supplementation may be initiated for 48–72 hours pre-operatively

• Informed consent process with family conducted in their preferred language via GAF's medical interpreter

• Anesthesia briefing; premedication plan finalized

PHASE 3 — THE PROCEDURE (Day 3 or 4)

• Open Surgical Repair: 3–5 hours total operative time (incision to closure), including CPB weaning and intraoperative TEE confirmation

• Transcatheter Closure: 1–2 hours in the catheterization laboratory; no general anesthesia scar; same-day or next-day discharge protocol

• Hybrid Repair: 2–3 hours in a combined OR/cath lab environment

• Immediate post-procedure transfer to the Pediatric Cardiac Intensive Care Unit (PCICU)

PHASE 4 — PCICU STAY (Days 4–7 for surgical; Days 4–5 for transcatheter)

• Mechanical ventilation: typically extubated within 4–8 hours post-open repair using fast-track cardiac anesthesia protocols (high-dose opioid-free or opioid-sparing regimens with dexmedetomidine)

• Continuous hemodynamic monitoring: arterial line, central venous pressure, near-infrared spectroscopy (NIRS) cerebral oximetry

• Vasoactive support (milrinone ± dopamine) weaned as cardiac output improves

• Chest drain output monitored; drains removed when output < 3 mL/kg/hour for 4 consecutive hours

• Pain management: multimodal — regional nerve blocks, paracetamol, low-dose NSAIDs as renal function permits

• First post-operative echocardiogram performed before PCICU discharge to confirm patch integrity

PHASE 5 — STEP-DOWN WARD (Days 7–12)

• Transition to oral cardiac medications: diuretics tapered over 4–6 weeks, aspirin (post-device closure: 3–6 months antiplatelet therapy)

• Sternal precautions taught to caregivers (no lifting under the arms for 6–8 weeks post-sternotomy)

• Physiotherapy: deep breathing exercises, graduated mobility

• Wound care education; suture/staple removal if non-absorbable

• Repeat ECG and chest X-ray; echocardiogram on day 5–7 post-op

• Discharge planning: written summary, medications list, emergency contacts, outpatient cardiology follow-up schedule

PHASE 6 — POST-DISCHARGE, LOCAL RECOVERY (Weeks 2–6)

• Patient stays in GAF Healthcare-arranged accommodation near the hospital

• Outpatient cardiology review at 2-week post-discharge mark: clinical examination, echocardiogram, wound check

• Fit-to-fly clearance granted when: wound fully healed, no pleural or pericardial effusion on echo, stable rhythm on ECG, no oxygen requirement, and the treating cardiac surgeon formally documents approval

• For surgical patients: clearance typically at 4–6 weeks post-operatively

• For transcatheter patients: clearance typically at 2–3 weeks post-procedure

• Infective endocarditis (IE) prophylaxis: antibiotics recommended for 6 months post-device/patch implant for all dental, respiratory, and invasive procedures (per AHA/ESC guidelines)

PHASE 7 — HOME COUNTRY FOLLOW-UP

• GAF Healthcare coordinates transfer of a complete digital medical record package (operative notes, echocardiography images/reports, discharge summary, device/implant card) to the patient's home cardiologist

• Remote teleconsultation at 3 months, 6 months, and 12 months with the treating team facilitated by GAF Healthcare's telemedicine platform

• Annual echocardiographic surveillance recommended for 5 years post-repair